The project will support production for Aspen’s autologous cell therapy studies and future capacity needs for the company’s personalized medicines. The new 22,000-square-foot facility near ...

SAN DIEGO, Oct. 1, 2024 /PRNewswire/ -- Aspen Neuroscience, Inc., a private biotechnology company developing personalized (autologous) cell therapies, announced the expansion of its San Diego ...

I was having a problem with a bad tooth, caused a toothache and had made my side of my cheek swollen. I had an infection so they couldn't do anything till infection was taken care of. 5 days on ...

gene therapy, gene editing, tissue engineering, and broader regenerative medicine technologies, as well as over 100 panelists and featured speakers. Today, Aspen's CSO Dr. Zhang will present as a ...

This facility was designed and built for GMP manufacture and testing of Aspen's ANPD001 drug product, which is an iPSC-derived cell therapy for Parkinson's Disease (PD). Aspen will use the cells ...

Today, Aspen’s CSO Dr. Zhang will present as a member of a panel of industry experts. The 4 p.m. panel, “Science Slam: Neurological Diseases,” will focus on biomarkers and endpoints development for ...

This facility was designed and built for GMP manufacture and testing of Aspen’s ANPD001 drug product, which is an iPSC-derived cell therapy for Parkinson’s Disease (PD). Aspen will use the cells in ...

SAN DIEGO and PHOENIX, Oct. 7, 2024 /PRNewswire/ -- Presentations by Aspen Neuroscience Chief Scientific Officer Xiaokui Zhang, Ph.D. and Chief Technology Officer Kim Raineri will highlight the ...